Home Neoplasma Ahead of print neo_2020_191006N1009

Journal info


6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

neo_2020_191006N1009

Title: O-GlcNAcylation promotes malignant phenotypes of bladder cancer cells
Author: L. JIN, M.H. LU, G.C. DAI, Q. YAO, H. XIANG, L.X. WANG, B.X. XUE, X.L. LIU

Abstract: O-GlcNAcylation (O-GlcNAc) is a posttranslational modification that is mediated by O-GlcNAc-transferase (OGT) and reversed by O-GlcNAcase (OGA). Increasing evidence indicates that protein O-GlcNAcylation is increased in various types of cancer. In the present study, we aimed to evaluate the expression and function of both OGT and OGA in bladder cancer cells in vitro and in vivo. Expression data of OGT and OGA at the mRNA level was obtained from the Oncomine database. Effects of OGT and OGA on cell proliferate, invasive and migratory abilities were assessed using MTT, wound healing, cell invasive assay, and cell cycle analysis. In vivo assay was also performed in nude mice. The results revealed that the expression of OGT in bladder cancer tissues is higher than that of normal tissues, while the OGA level was found to be lower in cancer tissues. We also found that knockdown of OGT could inhibit cell proliferation, migration, invasion, and induce cell cycle arrest, while these are reversed when OGA is inhibited. We also observed that O-GlcNAcylation could promote tumor formation in vivo, compared with negative control. In summary, this study describes the oncogenic role of O-GlcNAcylation in bladder cancer cells.

Keywords: O-GlcNAcylation, OGT, OGA, bladder cancer
Published online: 16-Apr-2020
Year: , Volume: , Issue: Page From: , Page To:
doi:10.4149/neo_2020_191006N1009


download file



© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.